Vineet Laboratories Reports Zero Deviation in Rights Issue Fund Utilization for Sep'26
Vineet Laboratories Ltd · Others (Uncategorized) · 13 Nov 2026, 6:56 pm
Vineet Laboratories Reports Zero Deviation in Rights Issue Fund Utilization for Sep'26 Vineet Laboratories reported nil deviation in the utilization of proceeds from its ₹29.97 crore rights issue for the quarter ended 30th Sep'26. Of the total allocation, the company fully deployed ₹2.84 crore toward bank loan repayment and ₹6.71 crore toward general corporate purposes (against ₹6.71 crore allocated). Additionally, it utilized ₹8.88 crore out of ₹16.95 crore earmarked for production facility expansion and ₹0.34 crore out of ₹2.70 crore allocated for setting up an effluent treatment plant. CRISIL Ratings monitored the issue.
Original exchange filing (PDF)
More announcements from Vineet Laboratories Ltd
- Intimation-Newspaper publication of finaancial results of the quarter and half year ended 30.09.2026. · 16 Nov 2026
- Results for the quarter and half year ended 30.09.2026 · 12 Nov 2026
- Results for the quarter and Half year ended 30.09.2026 · 12 Nov 2026
- Vineet Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 12 Nov 2026
- Intimation of book closure regarding 10th Annual General Meeting · 07 Nov 2026
- Notice of 10th Annual general meeting of the company. · 07 Nov 2026
- Submission of Annual report for the FY 2025-26 · 07 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 · 12 Nov 2026
